261 related articles for article (PubMed ID: 23902720)
1. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review.
Nielsen OH; Loftus EV; Jess T
BMC Med; 2013 Jul; 11():174. PubMed ID: 23902720
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.
Moens A; van der Woude CJ; Julsgaard M; Humblet E; Sheridan J; Baumgart DC; Gilletta De Saint-Joseph C; Nancey S; Rahier JF; Bossuyt P; Cremer A; Dewit S; Eriksson C; Hoentjen F; Krause T; Louis E; Macken E; Milenkovic Z; Nijs J; Posen A; Van Hootegem A; Van Moerkercke W; Vermeire S; Bar-Gil Shitrit A; Ferrante M
Aliment Pharmacol Ther; 2020 Jan; 51(1):129-138. PubMed ID: 31692017
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review.
Huang W; Zhang X; Zhang L; Dai X; Chen H; Xie Q
BMC Pregnancy Childbirth; 2024 Apr; 24(1):251. PubMed ID: 38589784
[TBL] [Abstract][Full Text] [Related]
6. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease.
Deepak P; Stobaugh DJ
Aliment Pharmacol Ther; 2014 Nov; 40(9):1035-43. PubMed ID: 25164260
[TBL] [Abstract][Full Text] [Related]
7. Systematic review suggests TNF-α inhibitors may be rational options for pregnant patients with inflammatory bowel disease.
Levesque BG; Pountney-Levesque ME
Evid Based Med; 2014 Apr; 19(2):e15. PubMed ID: 24282175
[No Abstract] [Full Text] [Related]
8. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease.
Mahadevan U; Long MD; Kane SV; Roy A; Dubinsky MC; Sands BE; Cohen RD; Chambers CD; Sandborn WJ;
Gastroenterology; 2021 Mar; 160(4):1131-1139. PubMed ID: 33227283
[TBL] [Abstract][Full Text] [Related]
9. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).
Luu M; Benzenine E; Doret M; Michiels C; Barkun A; Degand T; Quantin C; Bardou M
Am J Gastroenterol; 2018 Nov; 113(11):1669-1677. PubMed ID: 29961771
[TBL] [Abstract][Full Text] [Related]
10. Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation.
Duricova D; Dvorakova E; Hradsky O; Mitrova K; Durilova M; Kozeluhova J; Kohout P; Zarubova K; Bronsky J; Hradska N; Bronska E; Adamcova M; Machkova N; Hruba V; Bortlik M; Lukas M; Malickova K; Lukas M
Inflamm Bowel Dis; 2019 Mar; 25(4):789-796. PubMed ID: 30239799
[TBL] [Abstract][Full Text] [Related]
11. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
[TBL] [Abstract][Full Text] [Related]
12. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis.
Komaki F; Komaki Y; Micic D; Ido A; Sakuraba A
J Autoimmun; 2017 Jan; 76():38-52. PubMed ID: 27913060
[TBL] [Abstract][Full Text] [Related]
13. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
Kanis SL; Modderman S; Escher JC; Erler N; Beukers R; de Boer N; Bodelier A; Depla ACTM; Dijkstra G; van Dijk ARM; Gilissen L; Hoentjen F; Jansen JM; Kuyvenhoven J; Mahmmod N; Mallant-Hent RC; van der Meulen-de Jong AE; Noruzi A; Oldenburg B; Oostenbrug LE; Ter Borg PCJ; Pierik M; Romberg-Camps M; Thijs W; West R; de Lima A; van der Woude CJ;
Gut; 2021 Jul; 70(7):1266-1274. PubMed ID: 33046558
[TBL] [Abstract][Full Text] [Related]
14. Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis.
Wang H; Hu Y; Chen F; Shen M
BMC Pregnancy Childbirth; 2022 Nov; 22(1):854. PubMed ID: 36402978
[TBL] [Abstract][Full Text] [Related]
15. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
16. The use of biologic therapy in pregnancy: a gastroenterologist's perspective.
Hassid B; Mahadevan U
Curr Opin Rheumatol; 2014 May; 26(3):347-53. PubMed ID: 24625373
[TBL] [Abstract][Full Text] [Related]
17. Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis.
Gubatan J; Nielsen OH; Levitte S; Juhl CB; Maxwell C; Streett SE; Habtezion A
Am J Gastroenterol; 2021 Feb; 116(2):243-253. PubMed ID: 33110017
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.
Chaparro M; Verreth A; Lobaton T; Gravito-Soares E; Julsgaard M; Savarino E; Magro F; Biron AI; Lopez-Serrano P; Casanova MJ; Gompertz M; Vitor S; Arroyo M; Pugliese D; Zabana Y; Vicente R; Aguas M; Shitrit BA; Gutierrez A; Doherty GA; Fernandez-Salazar L; Cadilla MJ; Huguet JM; OʼToole A; Stasi E; Marcos MN; Villoria A; Karmiris K; Rahier JF; Rodriguez C; Palomares DM; Fiorino G; Benitez JM; Principi M; Naftali T; Taxonera C; Mantzaris G; Sebkova L; Iade B; Lissner D; Bradley FI; Roman LA; Marin-Jimenez I; Merino O; Sierra M; Van Domselaar M; Caprioli F; Guerra I; Peixe P; Piqueras M; Rodriguez-Lago I; Ber Y; van Hoeve K; Torres P; Gravito-Soares M; Rudbeck-Resdal D; Bartolo O; Peixoto A; Martin G; Armuzzi A; Garre A; Donday MG; de Carpi MFJ; Gisbert JP
Am J Gastroenterol; 2018 Mar; 113(3):396-403. PubMed ID: 29460920
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies.
de Lima-Karagiannis A; Zelinkova-Detkova Z; van der Woude CJ
Am J Gastroenterol; 2016 Sep; 111(9):1305-12. PubMed ID: 27349339
[TBL] [Abstract][Full Text] [Related]
20. Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study.
Kanis SL; de Lima-Karagiannis A; de Boer NKH; van der Woude CJ
Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1232-1241.e1. PubMed ID: 28342949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
